TPCW
SMMT icon

TD Private Client Wealth’s Summit Therapeutics SMMT Stock Holding History

TD Private Client Wealth’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08K Hold
74
– – ﹤0.01% 1463
2026
Q1 		$1.4K Hold
74
– – ﹤0.01% 1339
2025
Q4 		$1.29K Hold
74
– – ﹤0.01% 1328
2025
Q3 		$1.53K Hold
74
– – ﹤0.01% 1278
2025
Q2 		$1.57K Buy
+74
New +$1.69K ﹤0.01% 1251

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TD Private Client Wealth's SMMT Position: Q2 2026 in Review

TD Private Client Wealth held its Summit Therapeutics (SMMT) position steady in Q2 2026 at 74 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #1463.

TD Private Client Wealth first reported a position in SMMT in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.57K in Q2 2025. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • TD Private Client Wealth held 74 shares of Summit Therapeutics worth $1.08K as of Q2 2026.
  • TD Private Client Wealth left its Summit Therapeutics share count unchanged in Q2 2026.
  • Summit Therapeutics made up ﹤0.01% of TD Private Client Wealth's portfolio in Q2 2026, its #1463 holding.
  • TD Private Client Wealth first reported a position in Summit Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • TD Private Client Wealth's Summit Therapeutics position peaked at $1.57K in Q2 2025.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on TD Private Client Wealth's 13F filing for Q2 2026, filed 4 Aug 2026.